On December 15, the share price of Granules India will be closely watched after the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Hyderabad facility.
The facility, which is a wholly owned subsidiary of Granules Life Sciences, was inspected by the FDA from July 28, 2025, to August 1, 2025. The EIR confirms that the facility meets the FDA's quality standards and regulatory requirements.
Granules Life Sciences is involved in the manufacturing of pharmaceutical products, including PFI and finished dosages. The company has also made significant progress in sustainability, achieving the highest 'A' rating in Climate Change, a two-level improvement from the previous year.
In the previous trading session, the share price closed at Rs 574.50, up 1.68 percent. The stock has touched a 52-week high of Rs 621.10 and a 52-week low of Rs 412.05. Currently, the stock is trading 7.5 percent below its 52-week high and 39.42 percent above its 52-week low.
The market capitalization of the company stands at Rs 13,941.32 crore, making it a significant player in the pharmaceutical industry. With the US FDA approval and recent developments, Granules India is expected to remain in focus in the coming days.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join Telegram